PMID- 36707357
OWN - NLM
STAT- MEDLINE
DCOM- 20230620
LR  - 20240110
IS  - 1873-7560 (Electronic)
IS  - 0302-2838 (Linking)
VI  - 84
IP  - 1
DP  - 2023 Jul
TI  - Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium 
      Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic 
      Renal Cell Carcinoma.
PG  - 109-116
LID - S0302-2838(23)00001-5 [pii]
LID - 10.1016/j.eururo.2023.01.001 [doi]
AB  - BACKGROUND: The combination of immuno-oncology (IO) agents ipilimumab and 
      nivolumab (IPI-NIVO) and vascular endothelial growth factor targeted therapies 
      (VEGF-TT) combined with IO (IO-VEGF) are current standard of care first-line 
      treatments for metastatic renal cell carcinoma (mRCC). OBJECTIVE: To establish 
      real-world clinical benchmarks for IO combination therapies based on the 
      International mRCC Database Consortium (IMDC) criteria. DESIGN, SETTING, AND 
      PARTICIPANTS: Patients with mRCC who received first-line IPI-NIVO, IO-VEGF, or 
      VEGF-TT from 2002 to 2021 were identified using the IMDC database and stratified 
      according to IMDC risk groups. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: 
      Overall survival (OS), time to next treatment (TTNT), and treatment duration (TD) 
      were calculated using the Kaplan-Meier method and compared between IMDC risk 
      groups within each treatment cohort by the log-rank test. The overall response 
      rate (ORR) was calculated by physician assessment of the best overall response. 
      The primary outcome was OS at 18 mo. RESULTS AND LIMITATIONS: In total, 728 
      patients received IPI-NIVO, 282 IO-VEGF, and 7163 VEGF-TT. The median follow-up 
      times for patients remaining alive were 14.3 mo for IPI-NIVO, 14.9 mo IO-VEGF, 
      and 34.4 mo for VEGF-TT. OS at 18 mo for favorable, intermediate, and poor risk 
      was, respectively, 90%, 78%, and 50% for those receiving IPI-NIVO; 93%, 83%, and 
      74% for IO-VEGF; and 84%, 64%, and 28% for VEGF-TT. ORRs in favorable-, 
      intermediate-, and poor-risk groups were 41.3%, 40.6%, and 33.0% for those 
      receiving IPI-NIVO; 60.3%, 56.8%, and 40.9% for IO-VEGF; and 39.3%, 33.5%, and 
      20.9% for VEGF-TT, respectively. The IMDC model stratified patients into 
      statistically distinct risk groups for the three endpoints of OS, TTNT, and TD 
      within each treatment cohort. Limitations of this study were the retrospective 
      design and short follow-up. CONCLUSIONS: This study demonstrated that the IMDC 
      model continues to risk stratify patients with mRCC treated with contemporary 
      first-line IO combination therapies and provided real-world survival benchmarks. 
      PATIENT SUMMARY: The International Metastatic Renal Cell Carcinoma Database 
      Consortium model continues to stratify patients with metastatic renal cell 
      carcinoma receiving modern combination treatments in the real-world setting.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Ernst, Matthew S
AU  - Ernst MS
AD  - Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, 
      Calgary, Alberta, Canada.
FAU - Navani, Vishal
AU  - Navani V
AD  - Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, 
      Calgary, Alberta, Canada.
FAU - Wells, J Connor
AU  - Wells JC
AD  - Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, 
      Calgary, Alberta, Canada.
FAU - Donskov, Frede
AU  - Donskov F
AD  - Department of Oncology, Aarhus University Hospital & University Hospital of 
      Southern Denmark, Esbjerg, Denmark.
FAU - Basappa, Naveen
AU  - Basappa N
AD  - Cross Cancer Clinic, University of Alberta, Edmonton, Alberta, Canada.
FAU - Labaki, Chris
AU  - Labaki C
AD  - Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - Pal, Sumanta K
AU  - Pal SK
AD  - City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
FAU - Meza, Luis
AU  - Meza L
AD  - City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
FAU - Wood, Lori A
AU  - Wood LA
AD  - Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada.
FAU - Ernst, D Scott
AU  - Ernst DS
AD  - London Regional Cancer Centre, London, Ontario, Canada.
FAU - Szabados, Bernadett
AU  - Szabados B
AD  - Barts Cancer Institute, Queen Mary University of London, London, UK.
FAU - McKay, Rana R
AU  - McKay RR
AD  - University of California San Diego, Moores Cancer Center, San Diego, CA, USA.
FAU - Parnis, Francis
AU  - Parnis F
AD  - Icon Cancer Centre, Adelaide, South Australia.
FAU - Suarez, Cristina
AU  - Suarez C
AD  - Vall d'Hebron Institute of Oncology, Universitat Autonoma de Barcelona, 
      Barcelona, Spain.
FAU - Yuasa, Takeshi
AU  - Yuasa T
AD  - Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 
      Japan.
FAU - Lalani, Aly-Khan
AU  - Lalani AK
AD  - Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.
FAU - Alva, Ajjai
AU  - Alva A
AD  - University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.
FAU - Bjarnason, Georg A
AU  - Bjarnason GA
AD  - Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
FAU - Choueiri, Toni K
AU  - Choueiri TK
AD  - Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - Heng, Daniel Y C
AU  - Heng DYC
AD  - Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, 
      Calgary, Alberta, Canada. Electronic address: Daniel.Heng@AHS.ca.
LA  - eng
PT  - Journal Article
DEP - 20230126
PL  - Switzerland
TA  - Eur Urol
JT  - European urology
JID - 7512719
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
EIN - Eur Urol. 2023 Jun;83(6):e166-e167. PMID: 36967358
CIN - Eur Urol. 2023 Jul;84(1):e16-e17. PMID: 37061446
CIN - Eur Urol. 2023 Jul;84(1):e18-e19. PMID: 37080894
CIN - Eur Urol. 2023 Oct;84(4):e96-e97. PMID: 37391304
CIN - Eur Urol. 2023 Dec;84(6):e143-e144. PMID: 37661553
MH  - Humans
MH  - *Carcinoma, Renal Cell/pathology
MH  - Prognosis
MH  - *Kidney Neoplasms/pathology
MH  - Vascular Endothelial Growth Factor A
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Immunotherapy
OT  - International Metastatic Renal Cell Carcinoma Database Consortium
OT  - Metastatic renal cell carcinoma
OT  - Prognostication
OT  - Vascular endothelial growth factor targeted therapy
EDAT- 2023/01/28 06:00
MHDA- 2023/06/20 06:42
CRDT- 2023/01/27 22:03
PHST- 2022/07/21 00:00 [received]
PHST- 2022/11/24 00:00 [revised]
PHST- 2023/01/06 00:00 [accepted]
PHST- 2023/06/20 06:42 [medline]
PHST- 2023/01/28 06:00 [pubmed]
PHST- 2023/01/27 22:03 [entrez]
AID - S0302-2838(23)00001-5 [pii]
AID - 10.1016/j.eururo.2023.01.001 [doi]
PST - ppublish
SO  - Eur Urol. 2023 Jul;84(1):109-116. doi: 10.1016/j.eururo.2023.01.001. Epub 2023 
      Jan 26.